• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk stratification in PAH.

作者信息

Corris Paul A

机构信息

Emeritus Professor of Thoracic Medicine, Newcastle University, Newcastle, UK.

出版信息

Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202009. doi: 10.21542/gcsp.2020.9.

DOI:10.21542/gcsp.2020.9
PMID:33150153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7590928/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/fc5e0271441a/gcsp-2020-1-e202009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/8fb6a747ab38/gcsp-2020-1-e202009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/fb689fc5f7e2/gcsp-2020-1-e202009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/fc5e0271441a/gcsp-2020-1-e202009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/8fb6a747ab38/gcsp-2020-1-e202009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/fb689fc5f7e2/gcsp-2020-1-e202009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/7590928/fc5e0271441a/gcsp-2020-1-e202009-g003.jpg

相似文献

1
Risk stratification in PAH.肺动脉高压的风险分层
Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202009. doi: 10.21542/gcsp.2020.9.
2
[Risk stratification methods and their significance in pulmonary arterial hypertension].[肺动脉高压的风险分层方法及其意义]
Ter Arkh. 2019 Sep 15;91(9):150-157. doi: 10.26442/00403660.2019.09.000192.
3
Risk stratification in pulmonary arterial hypertension.肺动脉高压的风险分层。
Curr Opin Pulm Med. 2018 Sep;24(5):407-415. doi: 10.1097/MCP.0000000000000510.
4
Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH).系统性硬化症相关肺动脉高压（SSc-PAH）治疗面临的挑战与进展
Ther Clin Risk Manag. 2019 Dec 13;15:1427-1442. doi: 10.2147/TCRM.S219024. eCollection 2019.
5
Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE).肺动脉高压的流行病学与初始管理：来自希腊肺动脉高压注册研究（HOPE）的真实世界数据
Pulm Circ. 2019 Oct 14;9(3):2045894019877157. doi: 10.1177/2045894019877157. eCollection 2019 Jul-Sep.
6
CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis.CCL21 作为系统性硬化症相关肺动脉高压的潜在血清生物标志物。
Arthritis Rheumatol. 2018 Oct;70(10):1644-1653. doi: 10.1002/art.40534. Epub 2018 Aug 30.
7
Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs.静息超声心动图测量在欧洲心脏病学会运动试验风险分层切点的基础上对肺动脉高压患者进行分类的作用。
Int J Cardiol. 2018 Apr 15;257:291-297. doi: 10.1016/j.ijcard.2018.01.042. Epub 2018 Jan 31.
8
The value of three-dimensional echocardiography in risk stratification in pulmonary arterial hypertension: a cross-sectional study.三维超声心动图在肺动脉高压风险分层中的价值：一项横断面研究。
Int J Cardiovasc Imaging. 2020 Apr;36(4):577-584. doi: 10.1007/s10554-019-01743-1. Epub 2019 Dec 18.
9
Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort.DETECT 算法前后边界性肺动脉高压的频率：来自前瞻性系统性硬化症队列的结果。
Rheumatology (Oxford). 2018 Mar 1;57(3):480-487. doi: 10.1093/rheumatology/kex435.
10
Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension.血清尿酸作为系统性硬化症相关肺动脉高压疾病风险、严重程度及生存率的标志物。
Pulm Circ. 2019 Jul 29;9(3):2045894019859477. doi: 10.1177/2045894019859477. eCollection 2019 Jul-Sep.

引用本文的文献

1
Molecular Hydrogen Therapy in Sjögren's Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell.干燥综合征合并肺动脉高压和右心衰竭的分子氢治疗：免疫标志物包括 Treg、B 细胞和浆细胞改善的一例报告。
In Vivo. 2024 Nov-Dec;38(6):3117-3124. doi: 10.21873/invivo.13797.
2
The lamp of medicine of Ancient Egypt is still burning.古埃及的医学之灯仍在燃烧。
Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202016. doi: 10.21542/gcsp.2020.16.

本文引用的文献

1
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.肺动脉高压的风险评估、预后和指南实施。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017. Print 2017 Aug.
2
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.肺动脉高压死亡率：2015 年欧洲肺动脉高压指南风险分层模型预测。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00740-2017. Print 2017 Aug.
3
Update in treatment options in pulmonary hypertension.
肺动脉高压治疗选择的最新进展。
J Heart Lung Transplant. 2016 Jun;35(6):695-703. doi: 10.1016/j.healun.2016.01.020. Epub 2016 Jan 15.
4
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.BMPR2 突变与肺动脉高压患者生存：一项个体参与者数据荟萃分析。
Lancet Respir Med. 2016 Feb;4(2):129-37. doi: 10.1016/S2213-2600(15)00544-5. Epub 2016 Jan 19.
5
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会（ESC）/欧洲呼吸学会（ERS）肺动脉高压诊断和治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断和治疗联合工作组：得到以下组织认可：欧洲儿科和先天性心脏病协会（AEPC）、国际心肺移植学会（ISHLT）。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
6
Management of pulmonary arterial hypertension.肺动脉高压的管理。
J Am Coll Cardiol. 2015 May 12;65(18):1976-97. doi: 10.1016/j.jacc.2015.03.540.
7
Managing pulmonary arterial hypertension and optimizing treatment options: prognosis of pulmonary artery hypertension.管理肺动脉高压和优化治疗选择：肺动脉高压的预后。
Am J Cardiol. 2013 Apr 16;111(8 Suppl):10C-5C. doi: 10.1016/j.amjcard.2013.01.319.
8
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.REVEAL 登记研究风险评分计算器在肺动脉高压初诊患者中的应用。
Chest. 2012 Feb;141(2):354-362. doi: 10.1378/chest.11-0676. Epub 2011 Jun 16.
9
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).预测肺动脉高压患者的生存情况：来自评估早期和长期肺动脉高压疾病管理登记研究（REVEAL）的见解。
Circulation. 2010 Jul 13;122(2):164-72. doi: 10.1161/CIRCULATIONAHA.109.898122. Epub 2010 Jun 28.
10
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.特发性、家族性和与厌食剂相关的肺动脉高压患者在现代管理时代的生存情况。
Circulation. 2010 Jul 13;122(2):156-63. doi: 10.1161/CIRCULATIONAHA.109.911818. Epub 2010 Jun 28.